Embecta (NASDAQ:EMBC) Posts Quarterly Earnings Results, Beats Estimates By $0.20 EPS

Embecta (NASDAQ:EMBC) released its quarterly earnings data on Thursday. The company reported $0.65 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.20, Zacks reports. Embecta had a net margin of 6.97% and a negative return on equity of 18.54%. Embecta updated its FY 2025 guidance to 2.700-2.900 EPS.

Embecta Stock Down 3.5 %

Shares of EMBC stock traded down $0.64 during trading on Thursday, reaching $17.56. The company’s stock had a trading volume of 276,465 shares, compared to its average volume of 365,379. The company has a market cap of $1.02 billion, a price-to-earnings ratio of 12.97, a price-to-earnings-growth ratio of 0.97 and a beta of 1.20. Embecta has a one year low of $9.93 and a one year high of $21.48. The business has a fifty day moving average price of $19.70 and a 200-day moving average price of $16.52.

Embecta Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, December 18th. Stockholders of record on Friday, December 6th were paid a dividend of $0.15 per share. The ex-dividend date was Friday, December 6th. This represents a $0.60 annualized dividend and a dividend yield of 3.42%. Embecta’s dividend payout ratio is currently 44.44%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. BTIG Research upgraded Embecta from a “neutral” rating to a “buy” rating and set a $26.00 price objective on the stock in a report on Wednesday, November 27th. Morgan Stanley raised shares of Embecta from an “underweight” rating to an “equal weight” rating and increased their price objective for the stock from $13.00 to $20.00 in a research report on Monday, December 2nd.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.